MacroGenics Inc stock (US5562221046): shares ease after strong year-to-date run amid biotech volatility

MacroGenics stock on Nasdaq traded slightly lower on 05/28/2026 after a strong year-to-date performance, as investors reassessed risks in the U.S. biotech sector following recent price swings and earlier earnings updates.

MacroGenics stock on the Nasdaq Global Select Market traded at USD 4.21 at the close on 05/28/2026, down 3.88% for the day, according to data from MarketBeat as of 05/28/2026. The move came after a period of sharp gains in 2026, during which the Maryland-based biotechnology name has been among the stronger performers in the U.S. healthcare space, while broader biotech benchmarks have seen heightened volatility.

The stock, which is listed in the United States under the ticker MGNX, has recorded a notable year-to-date advance in 2026 and was cited among significant gainers in the healthcare segment in year-to-date rankings. The latest pullback follows these earlier gains and reflects a broader pattern of profit-taking and risk rotation in U.S. small and mid-cap biotech names, even as company-specific news flow has been relatively quiet since its last reported quarterly results.

For Germany-based retail investors following the name via secondary trading venues, MacroGenics also trades in euros on platforms such as Tradegate, with pricing referencing the primary Nasdaq listing in the United States. Liquidity and spreads on these German venues typically depend on demand during European trading hours, while price discovery continues to be driven by the U.S. market close.

The stock traded at USD 4.21 on 05/28/2026 on Nasdaq, compared with an after-hours indication of USD 4.23 on the same date, according to MarketBeat as of 05/28/2026. This after-hours uptick of USD 0.02 highlighted modest buying interest following the regular session decline, but still left the shares below recent intraday levels reached earlier in May 2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: MGNX
• Sector/industry: Biotechnology / oncology-focused therapeutics
• Headquarters/country: Rockville, United States
• Core markets: United States, with partnering reach into global pharma markets
• Key revenue drivers: Antibody-based cancer therapies and partnered development programs
• Home exchange/listing venue: Nasdaq Global Select Market (MGNX)
• Trading currency: USD

MacroGenics Inc: core business model

MacroGenics develops and advances antibody-based oncology therapies and related immuno-oncology candidates, generating revenue primarily through a mix of product collaborations, milestone payments and, where applicable, commercial arrangements with larger pharmaceutical partners.

Valuation metrics and multiples for MacroGenics Inc

With Friday's focus on valuation, investors are closely watching how MacroGenics is priced relative to its fundamentals and peers in the U.S. biotechnology universe. Based on the 05/28/2026 closing price of USD 4.21, the company trades at levels below the average twelve-month price target of USD 5.50 reported by seven Wall Street analysts, according to MarketBeat as of 05/28/2026. This consensus price objective, with a documented high estimate of USD 9.00 and a low of USD 2.00, suggests that the current market price embeds a balance of risk and potential upside for a development-stage biotech platform.

The same MarketBeat overview indicates that MacroGenics is covered by seven sell-side analysts, who collectively assign a "hold" rating to the shares as of 05/28/2026, highlighting a neutral stance while the company continues to progress its pipeline. As a loss-making biotechnology developer that is still in a research and early commercialization phase, traditional earnings-based valuation ratios such as price-to-earnings are less meaningful, and investors tend to concentrate on cash runway, partnership economics and projected milestone inflows when assessing valuation.

Conclusion

MacroGenics shares have eased from recent levels on 05/28/2026, even after a strong year-to-date showing and a place among notable healthcare gainers, reflecting the shifting risk appetite in the U.S. biotech space. With the stock currently trading below the average twelve-month analyst price target while consensus remains at "hold," the valuation debate centers on how investors weigh pipeline execution and partnership economics against ongoing clinical and funding risks. For retail investors in the United States and Germany following the name, upcoming data readouts and any new collaboration announcements are likely to be key catalysts for reassessing both the share price and valuation framework.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.